TrialHepatology international2018

Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.

Namiki Izumi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.